Opioid Use Disorder: Assessment and Treatment Strategies for Counselors

The Opioid Crisis and Clinical Practice

Opioid Use Disorder (OUD) has become one of the most pressing public health challenges in the United States. With over 80,000 opioid-related overdose deaths annually, counselors play a critical role in assessment, treatment, and recovery support. Understanding OUD is essential for both clinical competence and counseling licensure exam success.

DSM-5-TR Diagnostic Criteria

OUD follows the same general diagnostic framework as other substance use disorders. A problematic pattern of opioid use leading to clinically significant impairment or distress is identified by at least two of eleven criteria within a 12-month period. These criteria mirror those of AUD and include impaired control (using more than intended, unsuccessful quit attempts, craving, excessive time spent), social impairment (role obligation failure, continued use despite problems, activity reduction), risky use (physically hazardous situations, use despite physical or psychological consequences), and pharmacological indicators (tolerance and withdrawal).

Important Note on Tolerance and Withdrawal

For individuals taking opioids as prescribed under medical supervision, tolerance and withdrawal alone do not warrant an OUD diagnosis. This distinction is important to avoid pathologizing appropriate medical use of opioid medications.

Clinical Presentation

Clients with OUD may present with constricted pupils, drowsiness, slurred speech, and impaired attention during intoxication. Between doses, they may show anxiety, restlessness, and drug-seeking behavior. Opioid withdrawal, while extremely uncomfortable, is generally not life-threatening (unlike alcohol or benzodiazepine withdrawal). Withdrawal symptoms include muscle aches, insomnia, lacrimation, rhinorrhea, diarrhea, nausea, vomiting, dilated pupils, piloerection (goosebumps), and yawning. Symptoms typically begin 8 to 24 hours after the last dose for short-acting opioids.

Medication-Assisted Treatment (MAT)

Medications for OUD (MOUD) are considered the standard of care and significantly reduce mortality, illicit opioid use, and criminal behavior.

Methadone

Methadone is a full opioid agonist administered through federally regulated Opioid Treatment Programs (OTPs). It prevents withdrawal, reduces cravings, and blocks the euphoric effects of other opioids. Daily supervised dosing is standard initially, with take-home privileges earned over time.

Buprenorphine

Buprenorphine is a partial opioid agonist that can be prescribed in office-based settings. It has a ceiling effect, making it safer in overdose than full agonists. Brand names include Suboxone (buprenorphine combined with naloxone) and Sublocade (extended-release injection). Federal regulations have expanded prescribing access to make buprenorphine more available.

Naltrexone

Naltrexone is an opioid antagonist that blocks opioid receptors, preventing any euphoric effects. It requires full detoxification before initiation. The extended-release injectable form (Vivitrol) improves adherence compared to daily oral dosing.

Psychosocial Treatments

Counseling is an essential component of comprehensive OUD treatment. Cognitive Behavioral Therapy helps clients identify triggers and develop coping skills. Contingency Management provides tangible reinforcement for positive behaviors such as negative drug screens. Motivational Interviewing addresses ambivalence and builds motivation for change. Community Reinforcement Approach (CRA) restructures the client's environment to make sobriety more rewarding than substance use. Twelve-step programs including Narcotics Anonymous provide peer support and structure.

Harm Reduction

Harm reduction is an increasingly important framework in OUD treatment. Naloxone (Narcan) distribution programs provide overdose reversal medication to individuals at risk and their families. Needle exchange programs reduce transmission of bloodborne infections. These approaches prioritize keeping individuals alive and healthy while supporting their movement toward recovery at their own pace.

Exam Tips

• Opioid withdrawal is extremely uncomfortable but generally not fatal (unlike alcohol and benzodiazepine withdrawal)
• Medication-Assisted Treatment is the evidence-based standard of care for OUD
• Know the three FDA-approved medications: methadone (full agonist), buprenorphine (partial agonist), naltrexone (antagonist)
• Naloxone is the overdose reversal agent; naltrexone is the long-term treatment antagonist
• Tolerance and withdrawal during prescribed medical use do not alone constitute a diagnosis
• Harm reduction approaches are evidence-based and clinically appropriate